← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Signalrx Pharmaceuticals, Inc.
Cumming, GA
$3,076,634
Total funding
5
Grants
Funding over time
peak $1.3M · FY2015–19$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$3,076,634 · 5
By mechanism
R42$1,968,269 · 1
R41$808,477 · 3
R43$299,888 · 1
Investigators at Signalrx Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523$1,320,558
R42 · FY2017 · CA
Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523$647,711
R42 · FY2018 · CA
Overcoming BTK inhibitor resistance in B-cell malignancies$299,888
R43 · FY2019 · CA
Maximizing cancer synthetic lethality using dual PI-3K/PARP inhibitors$299,738
R41 · FY2016 · CA
Discovery of novel CDK4/6-PI3K-BRD4 inhibitor SRX3177 for augmented anti-cancer activity$299,738
R41 · FY2018 · CA
Maximal MYC control using dual PI-3K/BRD4 (kinase/epigenetic) inhibitors$209,001
R41 · FY2015 · CA